All News
ICYMI: Psoriatic Arthritis and Pregnancy
Dr. Christina Chambers, an epidemiologist at the University of California San Diego and the principal investigator of MotherToBaby Pregnancy Studies, reviewed the available data on psoriatic arthritis and pregnancy. There is little evidence at this time that pregnancy affects PsA, though studies reliably demonstrate increase in disease activity in the post-partum period in both skin and joint disease.
Read Article
One in Ten has Autoimmune Disease
A UK population-based study suggests that autoimmune diseases affect approximately one in ten individuals.
Read Article
DDW 2023 study claims microscopic colitis (MC) pts had a 2fold higher risk of #RA. 11,293 MC pts matched 1:5 w/ population controls. With 8 yrs of F/U, RA was found in 1.1% of MC vs 0.6% controls (adj HR 1.92 (95% CI = 1.56-2.34). https://t.co/R5faYDoaAq https://t.co/qiaOMgOyLR
Links:
Dr. John Cush RheumNow ( View Tweet)
REMIT-UC: Tofacitinib study 334 w/ Ulcerative Colitis:Clinical remission in 35%, Endoscopic remission in ~24%; & low risk (per/100PY) of serious infections (2.1), H zoster (0.5), & VTE (1.1). Loss of response in 45%, but recaptured 55% w/ dose escalation https://t.co/OgQYcq9pQk https://t.co/1KtLDvkQGT
Links:
Dr. John Cush RheumNow ( View Tweet)
BMJ Systematic review of OP trials (69 RCTs, >80k pts) & Fx rates in postmenopausal F shows protective effect of bisphosphonates, PTH receptor agonists, & romosozumab vs PBO. Most effective PTHra > ROMO > Denosumab > bisphosphonates > PBO https://t.co/wKVCUnjmNT MJ
Links:
Dr. John Cush RheumNow ( View Tweet)
715 women w/ infertility from recurrent implantation failure were randomized to either placebo or prednisone 10 mg/d. Live birth rates were unaffected by pred (37.8% 38.8% w/ PBO; NS), but pred did increase rate of preterm deliveries (11.8% vs 5.5%; P=.04) https://t.co/ey5JDk2Xi5 https://t.co/Rcgphj147r
Links:
Dr. John Cush RheumNow ( View Tweet)
Treatment and Management of Neuropsychiatric Lupus
On the first day of ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus.
https://t.co/99GXxyIjLl https://t.co/Bor7R2qVtN
Links:
Dr. John Cush RheumNow ( View Tweet)
Stop RA trail:
Plaquenil didn’t prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023 @RheumNow https://t.co/gO9QKbAues https://t.co/gEpuBvDpj5
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023 @RheumNow
There are a lot of RA Rx on market now - do we need more?
Dr. Brenner: YES
Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/Og1vvbTRO9 https://t.co/WyqPH0lgkd
Links:
Dr. John Cush RheumNow ( View Tweet)
JAKinib safety takeaways
- avoid in older population 65 yo, malignancy, CV risk, VTE risk
- appropriate in younger pts without VTE/CVD risk factors
#RNL2023 @RheumNow https://t.co/mFvvqJ9Jbp https://t.co/A76tR2S1Rb
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023 @RheumNow
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/zncCw3jlK7 https://t.co/AHhDyxaumM
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Stanley Cohen on JAKinibs:
Very concise and informative timeline on the multiple JAKinibs approved for multiple conditions
@RheumNow #RNL2023 https://t.co/ulLh2HikUt https://t.co/0kR8CNZvsV
Links:
Dr. John Cush RheumNow ( View Tweet)
How do you prevent RA in at-risk patient?
Smoking cessation! Healthy weight and exercise! Diet! Periodontal health! 🚭🏋️🥕🦷
Education follow-up!
Not robustly proven to prevent/delay RA, but may be more important than early DMARD intervention! Kevin Deane, MD
#RNL2023
Dr. John Cush RheumNow ( View Tweet)
STOP-RA study on HCQ preventing RA...
HCQ did NOT prevent RA development in pre-RA pts
@RheumNow #RNL2023 https://t.co/uZRqAxWyyo https://t.co/02qUN4Hhrc
Links:
Dr. John Cush RheumNow ( View Tweet)
Heart to Heart: Cardiovascular Risk in RA
Tune in to hear experts discuss cardiovascular risk assessment, patient education, and the importance of disease control in the latest therapeutic update sponsored by AbbVie US Medical Affairs.
https://t.co/qfnayksf3q https://t.co/7D62APLK4Z
Links:
Dr. John Cush RheumNow ( View Tweet)
Full Read comprehensive revie by Isenberg on what Rx work in SLE; they review RCT data on approved drugs and Rx in development:
- Obinutuzumab
- Dapirolizumab
- Deucravacitinib
- Litifilimab
- Atacicept
- Telitacicept https://t.co/WZQ3soseDB https://t.co/UdkmFYhbGv
Links:
Dr. John Cush RheumNow ( View Tweet)
COMING UP NEXT! Join us May 9th for our next Tuesday Night Rheumatology. We'll be focusing on Modern Management of Psoriatic Arthritis
Remission in Psoriatic Arthritis
JAK inhibitors in Psoriasis and PsA
Pregnancy in PsA
https://t.co/8HZZAO1qIX https://t.co/UPGYXqGGu6
Links:
Dr. John Cush RheumNow ( View Tweet)
New download available!
RA Flares: Management and Risks
https://t.co/Ct1FXEueE2 https://t.co/7dsrJvu7hK
Links:
Dr. John Cush RheumNow ( View Tweet)
Tuesday Night Rheumatology: Rheumatoid Arthritis: Revolutionary Advances in Therapy
Check out this week's Tuesday Night Rheumatalogy focusing on RA.
https://t.co/oNu4XCY0ez https://t.co/Gll5Uraqwy
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch: Year of the JAKi
https://t.co/NaZn8w1YYY https://t.co/GzhQpz8ZfM
Links:
Dr. John Cush RheumNow ( View Tweet)